Evidence map›Paper›PMID 15372081›Full record

ReviewNature reviews. Microbiology2004

Antivirals and antiviral strategies.

Erik De Clercq

Open access · bronzeAbstract readReview
In one paragraph

Review in Nature reviews. Microbiology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 143 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
143citing papers in PubMed, 1 pooled it
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

143 citing papers in PubMed, 1 synthesis or guideline pooled it, 371 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Antiviral Drug Design: Past, Presence, and Future.Advances in experimental medicine and biology · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. AssessingThe veterinary quarterly · 2024
    Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Anionic Synthetic Polymers Prevent Bacteriophage Infection.Journal of the American Chemical Society · 2023
    Article
  19. Article
  20. Article

83 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Erik De ClercqRega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium. erik.declercq@rega.kuleuven.ac.be
Rega Institute for Medical Research · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, the demand for new antiviral strategies has increased markedly. There are many contributing factors to this increased demand, including the ever-increasing prevalence of chronic viral infections such as HIV and hepatitis B and C, and the emergence of new viruses such as the SARS coronavirus. The potential danger of haemorrhagic fever viruses and eradicated viruses such as variola virus being used as bioterrorist weapons has also increased the profile of antiviral drug discovery. Here, the virus infections for which antiviral therapy is needed and the compounds that are available, or are being developed, for the treatment of these infections are described.

Indexed as

AdenosylhomocysteinaseAntiviral AgentsDNA HelicasesHumansIMP DehydrogenaseInterferonsNucleic Acid Synthesis InhibitorsNucleoside-TriphosphataseRNA-Dependent RNA PolymeraseViral ProteinsVirus DiseasesVirusesAdenosylhomocysteinaseAntiviral AgentsDNA HelicasesIMP DehydrogenaseInterferonsNucleic Acid Synthesis InhibitorsNucleoside-TriphosphataseRNA-Dependent RNA PolymeraseViral Proteins

Identifiers

PMID15372081
PMCPMC7097272
OpenAlexW2079835503

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.